Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope you didn't.....
Collaspe..
Unexpected ugly drop..
Announcement? They just had a briefing yesterday.. No shot..
Looking good. We needed this..
There is a reason the market cap is minuscule.....
The typical consumer will not in anyway know the difference with EPA vs DHA. They will both be tainted with the confusion..
This REALLY is negative news...
This formulation is really an unknown unknown..
https://www.webmd.com/heart-disease/news/20201116/prescription-strength-fish-oil-wont-help-your-heart----or-will-it
A hallelujah move!!!
“Yes. I've been selling puts every month for the last few months with strikes in the 12-15 range. Assigned or not I'm happy either way.”
Looks like you are adding to your collection, nfrtna...
This is going to the March low..
I sold some as the call indicated it will be a slow slog.
PFE has clinical data that their vaccine works. SRNE...not sure what they have
This should be jail time for Ji:
Sorrento Therapeutics will announce their discovery of the STI-1499 antibody, which the San Diego company said can provide "100% inhibition" of COVID-19, adding that a treatment could be available months before a vaccine hits the market.
"We want to emphasize there is a cure. There is a solution that works 100 percent," Dr. Henry Ji, founder, and CEO of Sorrento Therapeutics, told Fox News. "If we have the neutralizing antibody in your body, you don't need the social distancing. You can open up a society without fear."
That certainly wasn't true and the company should have been suspended by the SEC.
From mad money tonight:
Sorrento Therapeutics: “I don’t think that you want to be in that stock. I think that we’ve now seen what it take to be a winner in this space, and they don’t have it.”
I hope Jess is right too. Lots of hard earned money sunk into this..
Ganz, it is what you posted:
“Great point church, I totally agree, just depends how it plays out.I hope we hold out for approval and distribution, ******but a savvy big cap Pharma, would have tremendous leverage offering a price before FDA approval*****. I hope, when that happens, AUPH refrains.”
Ganz, you think like Jess: “Wainwright is the only semi reputable brokerage firm that lists AUPH as a buy currently.”
Wonder why....(?)
Wainwright is the brokerage that is the underwriter for Aurina stock offerings..
No reason for this except to create ill will..
Trump Replaces FERC Chairman Neil Chatterjee With Commissioner James Danly
A surprising switch at the federal agency that’s passed market regulations opposed by states pursuing clean energy policies.
https://www.greentechmedia.com/articles/read/trump-replaces-ferc-chairman-neil-chatterjee-with-commissioner-james-danly?utm_medium=email&utm_source=Solar&utm_campaign=GTMSolar
Ganz, your logic is a bit amiss.. Big Pharma knows what they are dealing with here and will absolutely not make an offer for the Aurinia assets until the FDA decision. Can you imagine a big Pharma CEO going to their BOD and telling them they were certain Aurina’s LN compound worked after they received a rejection letter from the FDA, just after Aurinia received a ph 2 DES fail?? No they certainly aren’t that dumb they will wait for results..
If Aurinia starts to open sales offices and hiring a salesforce, then that would be a tell and unfortunate. A slow slog and a big dilution. Peter knows better...
Trial against Vascepa fully enrolled..
Bio Stocks™
??@BioStocks??
$MTNB ENHANCE-IT study of MAT9001 against Vascepa fully enrolled. Topline data anticipated Q1. $AMRN
11/6/20, 7:02 AM
$MTNB ENHANCE-IT study of MAT9001 against Vascepa fully enrolled. Topline data anticipated Q1. $AMRN
— Bio Stocks™ (@BioStocks) November 6, 2020
Need to go OTC to save this..
Glad I don’t own this. CEO is questionable...
I know Ariad and I know Aurina; Aurina is no Ariad... From Mr. Benson..
Romper room..
Someone else agrees with my synopsis:
“$AUPH Dry eye trials are hard, but Aurinia should have let eye experts run the trials from the get-go. P2 trial mishap (testing for ocular discomfort within a minute of distillation instead of 24 hrs) was a sign of things to come. Lost a pound to save a penny. VOS had potential.”
No need to..
Did Lunacy dump all his Aurinia shares? Is that why he doesn’t post here anymore?? Asking for a friend..
Slim, I wish you all the best in finding relief for your DES. I also take Vascepa for the medical benefit of the compound. I also see the discussions on using it for DES and I’m disappointed that it didn’t work for you as many posters claim it works wonders. Sharing results and ideas on treatments are what this is all about.
I become caustic on this board when I hear posters on this board who know nothing about the science boast that the stock will go to $45. Ignorance is sometimes bliss...
Slim, the rest of the biotech space disagrees with you on this from all the PR issued on the subject..
Now down over $2. Mr Market is now figuring out the consequences of this to Aurina.
Here is the just approved compound for DES that I would use. Will be the new blockbuster...
https://endpts.com/once-rejected-kalas-dry-eye-drug-now-gains-entry-to-a-field-where-novartis-is-grooming-its-own-blockbuster/
You NEVER abandon a compound that can add value to the buy out. It simply does not work. It reveals a lot about their skill set. As they now are forced to move forward creating a salesforce, I’m worried as they will have just one drug to sell for at least the next 7 years. Share count will now explode..
The drugs are related in that the whole Aurinia company is involved with both compounds. Investors will question the viability of their science in LN as well..
Following the NEE business model. Rapidly slashing CO2, re-defining the business..
The problem is their LN franchise just lost some intrinsic value. Now, any pharmaceutical company is clearly going to wait until trial results are revealed.. Hopefully it just temporarily damaged goods..
“You are saying they should have moved on from DES earlier. I am simply saying that maybe they are more likely to do so now. “
Nsomniyak, not more likely...They are killing the program...
This is ridiculous logic:
“Yes. There is a silver lining here. One possible scenario is that AUPH mgt was holding off on any negotiations re: licensing or even a b/o with hope the DES could provide a revaluation upward.
Assuming DES is a fail, maybe now they can proceed to do a deal based on LN and get that done.”
First off, they had zero experience with DES, second in their first trial, they picked the wrong end point. They based the DES trial on achieving superior patient comfort and not efficacy. Comfort missed but efficacy beat the standard of care. Knowing they had zero experience with DES, they should have stopped it right there and handed it off to an IST.
Mayberry RFD
https://m.imdb.com/title/tt0062587/
Jess, first Ariad now Aurinia. Bad picking..